Lisdexamfetamine

Introduction Overview

Generic Name

lisdexamfetamine

Brand Name

Vyvanse

Dosage Form

capsules, chewable tablets

Drug Class

CNS stimulants

Pharmacokinetics

Absorption: Lisdexamfetamine is a prodrug of dextroamphetamine and is absorbed primarily through the gastrointestinal tract following oral administration. It is rapidly and efficiently absorbed, with onset of pharmacological effects beginning within 1.5 to 2 hours depending on the patient’s age and individual variation. The prodrug requires enzymatic hydrolysis within the blood, predominantly by red blood cell enzymes, to release the active component, dextroamphetamine, which then exerts central nervous system stimulant effects. Food does not substantially affect the rate or extent of lisdexamfetamine absorption, allowing dosing with or without meals.

Distribution: Once converted to dextroamphetamine, the drug is widely distributed throughout the body, including the central nervous system. Dextroamphetamine crosses the blood-brain barrier readily to produce its therapeutic effects. Plasma protein binding of dextroamphetamine is moderate, approximately 20%, facilitating its availability in tissues and organs. The volume of distribution is estimated to be about 2.2 L/kg in adults, indicating extensive distribution into body tissues.

Metabolism: Lisdexamfetamine itself undergoes minimal hepatic metabolism. Its activation depends mainly on enzymatic hydrolysis via red blood cells, releasing dextroamphetamine and L-lysine. Dextroamphetamine is primarily metabolized in the liver through oxidative deamination and aromatic hydroxylation mediated by cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4 isoforms. Metabolic pathways also include conjugation processes leading to various inactive metabolites. Genetic polymorphisms in CYP450 enzymes can influence the metabolism rate of dextroamphetamine, impacting drug efficacy and tolerability.

Elimination: Dextroamphetamine is eliminated primarily via renal excretion, with approximately 30-40% excreted unchanged in the urine. The elimination half-life in adults is approximately 10 to 13 hours, though this can vary depending on urinary pH—acidic urine accelerates renal clearance, whereas alkaline urine slows it. Complete elimination usually occurs over roughly 60 hours (about 5 half-lives). Minor elimination pathways include fecal excretion of metabolites. In patients with renal impairment, clearance is reduced, warranting careful monitoring and potential dose adjustments.

Dosage Forms

Available Dosage Forms: Vyvanse is available in oral capsules and chewable tablets with a wide range of strengths to facilitate individualized dosing. The oral capsules are formulated in the following strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg of lisdexamfetamine dimesylate. Chewable tablets are available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg strengths, providing an alternative for patients who have difficulty swallowing capsules.

Dosages for Adults and Adolescents: For Attention Deficit Hyperactivity Disorder (ADHD), the initial dose in both adults and children aged 6 years and older typically starts at 30 mg once daily in the morning. Dosage titration can proceed in increments of 10 mg or 20 mg at approximately weekly intervals based on therapeutic response and tolerability, within a dosage range of 30 mg to 70 mg daily. For moderate to severe binge eating disorder in adults, starting doses often mirror those for ADHD, but treatment response may take up to 12 weeks to become evident, with titration adjusted accordingly.

Specific Patient Populations: Vyvanse is not FDA-approved for use in children younger than 6 years or for binge eating disorder patients under 18 years of age. In patients with renal impairment, particularly severe impairment, pharmacokinetics may be altered, necessitating careful dosing and monitoring although specific dosing adjustments have not been formally established. The drug is not recommended for patients with known hypersensitivity to amphetamines, or those who have used monoamine oxidase inhibitors within the prior 14 days. Pregnant and breastfeeding women should avoid Vyvanse, as it may harm the fetus or pass into breast milk. Special consideration should be given to patients with a history of cardiovascular disease, psychiatric conditions, or substance dependence due to increased risk of adverse effects.

Mechanism Of Action

Lisdexamfetamine is a pharmacologically inactive prodrug that, upon enzymatic hydrolysis, releases the active molecule dextroamphetamine. Dextroamphetamine primarily acts as a central nervous system stimulant by increasing the synaptic concentrations of monoamines, mainly dopamine and norepinephrine, through the promotion of their release and inhibition of their reuptake in nerve terminals. This activity primarily occurs within the prefrontal cortex and basal ganglia, brain regions integral to attention, impulse control, and executive functioning.

At a molecular level, dextroamphetamine enters presynaptic neurons via the dopamine transporter (DAT) and norepinephrine transporter (NET), displacing endogenous neurotransmitters from synaptic vesicles into the cytosol. Subsequently, these monoamines are transported into the synaptic cleft, augmenting neurotransmission. The increased dopaminergic and noradrenergic activity enhances neuronal firing and connectivity, which correlates clinically with improved attention span, reduced hyperactivity, and diminished impulsivity.

Comparative pharmacodynamic studies indicate that lisdexamfetamine, through its prodrug status, has a slower onset and longer duration of effect compared to immediate-release amphetamines like Adderall. This pharmacokinetic profile contributes to lower potential for abuse and a smoother therapeutic effect without pronounced peaks and troughs. Clinical trials demonstrate symptom improvement in ADHD and reductions in binge eating episodes via modulation of neural circuits implicated in behavioral regulation.

Research further supports that the activation of dopaminergic pathways by dextroamphetamine mediates enhanced alertness, cognition, and mood stabilization. However, prolonged stimulation may lead to adaptive neurochemical changes associated with tolerance and risk of dependence. The therapeutic efficacy balanced against these risks positions lisdexamfetamine as a valuable agent in managing ADHD and binge eating disorder under medical supervision.

Pharmacological Actions

Central nervous system stimulation through increased release of dopamine and norepinephrine.
Prodrug activation via enzymatic hydrolysis to release active dextroamphetamine.
Enhanced dopaminergic and noradrenergic neurotransmission in brain regions governing attention and impulse control.
Improvement of executive function, attention span, and reduction in hyperactivity and impulsivity.
Modulation of neural pathways involved in reward and behavioral regulation, beneficial in binge eating disorder.
Longer onset and sustained duration of action compared to immediate-release amphetamines, reducing abuse potential.
Minimal direct hepatic metabolism of prodrug; activation by red blood cell enzymes.
Dose-dependent pharmacodynamic effects with titratable therapeutic window.
Potential for developing tolerance and dependence with prolonged use requiring monitoring.
Limited peripheral sympathomimetic effects compared to older stimulant formulations.
Reduction of binge eating episodes via central appetite and impulse control pathways.
Improvement of cognitive functions such as working memory and processing speed in ADHD patients.
Neurochemical modulation contributing to mood stabilization effects.
Treatment of ADHD symptoms with improved safety profile over non-prodrug amphetamines.
Dextroamphetamine acts as substrate for monoamine transporters, facilitating neurotransmitter displacement.

Therapeutic Or Clinical Uses

Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older, adolescents, and adults.
Management of moderate to severe binge eating disorder in adults to reduce frequency of binge episodes.
Alternative agent for patients intolerant or nonresponsive to other CNS stimulant therapies.
Adjunct in behavioral therapy programs targeting impulse control and attention deficits.
Off-label use in patients with comorbid ADHD and mood disorders under specialist supervision.
Improvement of attention span, impulse regulation, and executive functioning.
Treatment option for patients requiring longer duration of stimulant effect with once-daily dosing.
Use in clinical situations where minimizing abuse potential is a priority due to prodrug formulation.
Management of ADHD symptoms in patients with a history of substance abuse under careful medical oversight.
Reduction in functional impairment and academic performance enhancement in pediatric ADHD.
Symptomatic treatment of binge eating disorder symptoms contributing to improved psychosocial outcomes.
Potential therapeutic use as part of multidisciplinary treatment plans for ADHD and BED.
Selected for patients with difficulty swallowing tablets due to availability of chewable formulations.
Utilized in clinical practice for sustained symptom control over 12 to 14 hours following morning dosing.
FDA-approved indication consistent with evidence-based guidelines and clinical trial data.

Side Or Adverse Effects

Dry mouth (xerostomia) frequently reported during therapy.
Loss of appetite leading to weight loss in some patients.
Insomnia or difficulty falling and staying asleep due to stimulant effects.
Increased heart rate (tachycardia) and palpitations in sensitive individuals.
Anxiety, nervousness, or feelings of jitteriness and irritability.
Dizziness and occasional headaches associated with CNS stimulation.
Gastrointestinal disturbances including nausea, vomiting, abdominal pain, diarrhea, and constipation.
Possible emergence or exacerbation of psychotic or manic symptoms, especially in susceptible individuals.
Peripheral vasculopathy symptoms manifesting as numbness, pain, discoloration in extremities (Raynaud's phenomenon).
Risk of cardiovascular adverse events such as chest pain and elevated blood pressure.
Rare hypersensitivity reactions including rash, hives, and angioedema.
Potential for serotonin syndrome when combined with serotonergic medications.
Growth suppression in pediatric populations with prolonged therapy requiring monitoring.
Dependence and withdrawal symptoms following abrupt discontinuation.
In extreme overdose, symptoms may include restlessness, tremor, convulsions, severe agitation, and coma.

Precautions

Assess history of cardiovascular disease, congenital heart defects, and hypertension before prescribing.
Evaluate for history of psychiatric disorders including bipolar, psychosis, depression, and suicidal ideation.
Avoid use in patients who have taken monoamine oxidase inhibitors within the last 14 days due to risk of hypertensive crisis.
Use caution in patients with history of substance abuse or addiction due to potential for dependence.
Monitor growth in children regularly and adjust dosage as appropriate.
Screen for tics or family history of Tourette’s syndrome as stimulants may exacerbate these conditions.
Advise patients regarding potential for habit formation and instruct against sharing medication.
Adjust dosing or reconsider therapy in moderate to severe renal impairment.
Pregnant women should avoid this medication unless benefits clearly outweigh risks; assess pregnancy status prior to initiation.
Discontinue breastfeeding during treatment due to passage of drug into breast milk.
Caution with concomitant use of serotonergic drugs to minimize risk of serotonin syndrome.
Drivers and machine operators should be aware of the potential impact on alertness, especially during initial titration.
Regular monitoring of blood pressure and heart rate is recommended during therapy.
Educate patients to report any new or worsening psychiatric symptoms immediately.
Store medication securely to prevent accidental ingestion and misuse.

Warnings

Vyvanse is a controlled substance with potential for abuse and dependence.
Serious cardiovascular events including stroke, myocardial infarction, and sudden death have been reported in patients with pre-existing heart conditions.
Contraindicated in patients who have used monoamine oxidase inhibitors within 14 days due to severe interaction risks.
Can cause new or worsening psychotic or manic symptoms, particularly in patients with psychiatric history.
Potential for peripheral vasculopathy including Raynaud’s phenomenon causing pain and color changes in digits.
Risk of serotonin syndrome exists when combined with other serotonergic agents.
Overdose can be fatal and presents with severe neurological and cardiovascular symptoms.
Do not use in children under 6 years of age for ADHD or under 18 years for binge eating disorder due to lack of safety data.
Discontinue immediately if signs of hypersensitivity or allergic reactions develop.
Monitor closely for signs of abuse or misuse including unexplained behavior changes.
Withdrawal symptoms can occur after sudden cessation; tapering recommended under physician supervision.
May impair cognitive and motor skills; patients should use caution when driving or operating machinery.
Exacerbation of bipolar disorder or emergence of suicidal thoughts necessitates prompt evaluation.
Abrupt discontinuation can result in fatigue, depression, and sleep disturbances.
Not indicated nor recommended for obesity or weight loss treatment.

Contraindication

Hypersensitivity to lisdexamfetamine or any component of the formulation.
Use of monoamine oxidase inhibitors within 14 days prior to initiation or during therapy.
Known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias.
Patients with diagnosed moderate to severe hypertension uncontrolled by therapy.
History of drug abuse or dependence contraindicating stimulant therapy in some cases.
Current or past diagnosis of glaucoma due to potential for increased intraocular pressure.
Hyperthyroidism or thyrotoxicosis due to exacerbation risks.
Concurrent use with other CNS stimulants not prescribed by a healthcare provider.
Known hypersensitivity to amphetamines or sympathomimetic amines.
Severe anxiety, tension, or agitation as stimulants may worsen these conditions.
Concurrent use with other medications that may cause serotonin syndrome.
Patients with known peripheral vasculopathy not medically managed.
Use in children under age 6 for ADHD and under 18 for binge eating disorder due to lack of approval.
Pregnant or breastfeeding women unless benefits outweigh potential risks.
Concomitant use with ergot alkaloids or other vasoconstrictors without clinical justification.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) – concurrent or recent use increases risk of hypertensive crisis.
Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol) – increased risk of serotonin syndrome.
Stomach acid reducers (antacids, sodium bicarbonate) – may alter lisdexamfetamine absorption and increase systemic exposure.
Other CNS stimulants (methylphenidate, amphetamines) – additive stimulant effects increase cardiovascular risk.
Antihypertensive medications – may reduce effectiveness due to stimulant-induced increase in blood pressure.
Tricyclic antidepressants – potential for pharmacodynamic interactions affecting cardiovascular system.
Antipsychotics – may antagonize therapeutic effects of amphetamines, requiring dose adjustments.
Opioid medications – combined use may increase risk of serotonin syndrome and CNS effects.
Drugs metabolized by CYP2D6 – potential altered metabolism of dextroamphetamine via enzyme inhibition or induction.
Anticonvulsants and mood stabilizers – may affect drug efficacy through pharmacokinetic interactions.
Warfarin and other anticoagulants – possible interaction requiring monitoring of coagulation parameters.
Herbal supplements with stimulant properties (ephedra, caffeine) – increased sympathomimetic effects.
Medications for migraine headaches (ergot alkaloids) – risk of vasoconstrictive adverse effects.
Linezolid or methylene blue – MAOI activity leading to hypertensive emergencies.
Drugs affecting renal pH – may alter excretion and plasma concentrations of dextroamphetamine.

Preparations Of The Drug

Vyvanse oral capsules available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg strengths for flexible dosing.
Vyvanse chewable tablets formulated in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg doses to aid patients with swallowing difficulties.
Capsules may be swallowed whole or contents can be dissolved in water, yogurt, or orange juice immediately before ingestion.
Chewable tablets must be thoroughly chewed prior to swallowing to ensure proper dosing.
Formulations are bioequivalent, allowing interchangeability under medical supervision.
Packaged in child-resistant containers to prevent accidental ingestion.
Storage recommended at room temperature, protected from moisture and heat to preserve stability.
No injectable, transdermal, or extended-release formulations are currently marketed under the Vyvanse brand.
Generic formulations of lisdexamfetamine dimesylate are available with similar pharmaceutical profiles.
Dosage forms designed to provide gradual conversion to active drug, minimizing abuse potential.
Commercial packaging often includes medication guides advising on abuse potential and safe storage.
Expiration dating consistent with stability studies indicating typical shelf-life of 2 to 3 years.
Manufactured under strict Good Manufacturing Practice (GMP) conditions to ensure purity and potency.
Formulations free of notable allergens except for inactive excipient allergens noted on labeling.
Patient information leaflets included to educate on administration, side effects, and precautions.